Charitable Contributions in 2019

Posted:
2
January 2020

As the 2019 year comes to an end, we would like to recognize the substantial charitable contributions made by the Richmond Pharmacology team; including our staff, academic

As the 2019 year comes to an end, we would like to recognize the substantial charitable contributions made by the Richmond Pharmacology team; including our staff, academic partners, collaborators and volunteers.Various initiatives have been undertaken including homeless sleep outs, bake sales, marathon events and Christmas Jumper day; all to raise money for those less fortunate than ourselves.

We would like to personally thank two very special volunteers, who decided to donate the payment they received from their study participants to the British Heart Foundation.At Richmond Pharmacology, our ethos is to improve the standard of living for millions of people through our research.

It is through generous donations, initiatives, and partnerships like these, that we are able to achieve our mission.

Notable donations throughout the year have been made to the following Charities

Looking to next year, 2020 promises to be another exciting year for Richmond Pharmacology and we look forward to continuing our charitable endeavors.Read letter of thanks from Robes

Latest news

Upcoming Event

EUFEMED, 3rd Annual Conference, 28-30 April 2021

28-30 April 2021
Dr Jorg Taubel will co-chair a session on day one, which explores how technology has reduced the risks of pandemic effects on Phase I and II trial performance.
View event

Richmond Pharmacology listed in the Alantra Pharma Fast 50

July 13, 2021
Richmond has been included in a top 50 list of the UK’s fastest-growing, privately-owned pharmaceutical businesses. 
Read more

Richmond Pharmacology listed in the J.P. Morgan Top 200 Female Powered Businesses

June 29, 2021
J.P. Morgan has identified Richmond Pharmacology as a high-growth female-powered business in its annual 'Top 200 Female Powered Businesses' list 2021.
Read more

CRISPR-Cas9 in-vivo gene editing shows reduction in TTR after a single dose

June 29, 2021
Data produced through Intellia Therapeutic’s NTLA-2001 FIH clinical trial, conducted at Richmond Pharmacology, indicates a reduction in the faulty TTR protein after a single infusion. Results were presented by Professor Julian Gillmore at this year’s Peripheral Nerve Society Annual Meeting.
Read more